Targeting hexokinase 2 to induce breast cancer cell senescence
Expressional shifts in the HK2/HK1 ratio may serve as a novel marker for BC cell senescence. Whereas targeting HK2 shows promise in untreated cancers, senescence-inducing anti-cancer therapies may limit the effectiveness of HK2-targeted treatments in pre-treated cancer patients.
Authors
- Robert Łukowski (ORCID: https://orcid.org/0000-0002-4564-3574)
- Katarina Cisarova (ORCID: https://orcid.org/0000-0003-2711-0480)
- Wolfgang F. Graier (ORCID: https://orcid.org/0000-0003-1871-3298)
- Roland Malli (ORCID: https://orcid.org/0000-0001-6327-8729)
- Markus Absenger‐Novak
- Sandra Burgstaller (ORCID: https://orcid.org/0000-0002-3926-7023)
- Helmut Bischof (ORCID: https://orcid.org/0000-0003-2380-600X)
- Philipp J. Jost (ORCID: https://orcid.org/0000-0003-2454-0362)
- Michael J. Schwerer
Institutions
- Medical University of Graz (AT)
- BioTechMed-Graz (AT)
- University of Tübingen (DE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-11-30
- DOI
- https://doi.org/10.1111/bph.70282
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00